Skip to content

Don’t invest unless you’re prepared to lose all the money you invest. You are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Month: September 2021

Northern Trust invests in Essentia Analytics

Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust (Nasdaq: NTRS) has reached an agreement to take an equity stake in Essentia Analytics, Ltd., … Continued

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Calculus strengthens Investor Relations team

Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the tax efficient third-party manager panel and driving distribution through product specialist support to Wealth Managers … Continued

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information